SMART: S_TKc domain annotation

S_TKc Serine/Threonine protein kinases, catalytic domain

SMART accession number:	SM00220
Description:	Phosphotransferases. Serine or threonine-specific kinase subfamily.
Interpro abstract (IPR002290):	Protein kinases are a group of enzymes that possess a catalytic subunit which transfers the gamma phosphate from nucleotide triphosphates (often ATP) to one or more amino acid residues in a protein substrate side chain, resulting in a conformational change affecting protein function. The enzymes fall into two broad classes, characterised with respect to substrate specificity: serine/threonine specific and tyrosine specific (PUBMED:3291115). Protein kinase function has been evolutionarily conserved from Escherichia coli to Homo sapiens. Protein kinases play a role in a mulititude of cellular processes, including division, proliferation, apoptosis, and differentiation (PUBMED:12368087). Phosphorylation usually results in a functional change of the target protein by changing enzyme activity, cellular location, or association with other proteins. The catalytic subunits of protein kinases are highly conserved, and several structures have been solved (PUBMED:15078142), leading to large screens to develop kinase-specific inhibitors for the treatments of a number of diseases (PUBMED:15320712). Eukaryotic protein kinases (PUBMED:7768349), (PUBMED:1835513), (PUBMED:1956325), (PUBMED:3291115) are enzymes that belong to a very extensive family of proteins which share a conserved catalytic core common with both serine/threonine and tyrosine protein kinases. There are a number of conserved regions in the catalytic domain of protein kinases. In the N-terminal extremity of the catalytic domain there is a glycine-rich stretch of residues in the vicinity of a lysine residue, which has been shown to be involved in ATP binding. In the central part of the catalytic domain there is a conserved aspartic acid residue which is important for the catalytic activity of the enzyme (PUBMED:1862342).
GO process:	protein amino acid phosphorylation (GO:0006468)
GO function:	protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524)
Family alignment:	View or

There are 14635 S_TKc domains in 14478 proteins in SMART's nrdb database.

Click on the following links for more information.

Evolution (species in which this domain is found)
Click on to expand nodes. To display all proteins with a S_TKc domain in a specific node, click on it.

This tree shows only several representative species. The complete taxonomic breakdown of all proteins with S_TKc domain is also avaliable.

Useful shortcuts: Expand all nodes or Collapse tree
Go to specific node: Anopheles gambiae, Arabidopsis thaliana, Caenorhabditis elegans, Drosophila melanogaster, Homo sapiens, Mus musculus, Rattus norvegicus, Saccharomyces cerevisiae, Takifugu rubripes
Cellular role (predicted cellular role)
Binding / catalysis: serine-specific phosphotransferase, threonine-specific phosphotransferase
Literature (relevant references for this domain)
Primary literature is listed below; Automatically-derived, secondary literature is also avaliable.
- Lewis TS, Shapiro PS, Ahn NG
- Signal transduction through MAP kinase cascades.
- Adv Cancer Res. 1998; 74: 49-139
- Engh RA, Girod A, Kinzel V, Huber R, Bossemeyer D
- Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity.
- J Biol Chem. 1996; 271: 26157-64
- Display abstract
- The discovery of several hundred different protein kinases involved in highly diverse cellular signaling pathways is in stark contrast to the much smaller number of known modulators of cell signaling. Of these, the H series protein kinase inhibitors (1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7), N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H8) N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89)) are frequently used to block signaling pathways in studies of cellular regulation. To elucidate inhibition mechanisms at atomic resolution and to enable structure-based drug design of potential therapeutic modulators of signaling pathways, we determined the crystal structures of corresponding complexes with the cAPK catalytic subunit. Complexes with H7 and H8 (2.2 A) and with H89 (2.3 A) define the binding mode of the isoquinoline-sulfonamide derivatives in the ATP-binding site while demonstrating effects of ligand-induced structural change. Specific interactions between the enzyme and the inhibitors include the isoquinoline ring nitrogen ligating to backbone amide of Val-123 and an inhibitor side chain amide bonding to the backbone carbonyl of Glu-170. The conservation of the ATP-binding site of protein kinases allows evaluation of factors governing general selectivity of these inhibitors among kinases. These results should assist efforts in the design of protein kinase inhibitors with specific properties.
- Hanks SK, Hunter T
- Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification.
- FASEB J. 1995; 9: 576-96
- Display abstract
- The eukaryotic protein kinases make up a large superfamily of homologous proteins. They are related by virtue of their kinase domains (also known as catalytic domains), which consist of approximately 250-300 amino acid residues. The kinase domains that define this group of enzymes contain 12 conserved subdomains that fold into a common catalytic core structure, as revealed by the 3-dimensional structures of several protein-serine kinases. There are two main subdivisions within the superfamily: the protein-serine/threonine kinases and the protein-tyrosine kinases. A classification scheme can be founded on a kinase domain phylogeny, which reveals families of enzymes that have related substrate specificities and modes of regulation.
- Owen DJ, Noble ME, Garman EF, Papageorgiou AC, Johnson LN
- Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product.
- Structure. 1995; 3: 467-82
- Display abstract
- BACKGROUND: Control of intracellular events by protein phosphorylation is promoted by specific protein kinases. All the known protein kinase possess a common structure that defines a catalytically competent entity termed the 'kinase catalytic core'. Within this common structural framework each kinase displays its own unique substrate specificity, and a regulatory mechanism that may be modulated by association with other proteins. Structural studies of phosphorylase kinase (Phk), the major substrate of which is glycogen phosphorylase, may be expected to shed light on its regulation. RESULTS: We report two crystal structures of the catalytic core (residues 1-298; Phk gamma trnc) of the gamma-subunit of rabbit muscle phosphorylase kinase: the binary complex with Mn2+/beta-gamma-imidoadenosine 5'-triphosphate (AMPPNP) to a resolution of 2.6 A and the binary complex with Mg2+/ADP to a resolution of 3.0 A. The structures were solved by molecular replacement using the cAMP-dependent protein kinase (cAPK) as a model. CONCLUSIONS: The overall structure of Phk gamma trnc is similar to that of the catalytic core of other protein kinases. It consists of two domians joined on one edge by a 'hinge', with the catalytic site located in the cleft between the domains. Phk gamma trnc is constitutively active, and lacks the need for an activatory phosphorylation event that is essential for many kinases. The structure exhibits an essentially 'closed' conformation of the domains which is similar to that of cAPK complexed with substrates. The phosphorylated residue that is located at the domain interface in many protein kinases and that is believed to stabilize an active conformation is substituted by a glutamate in Phk gamma trnc. The glutamate, in a similar manner to the phosphorylated residue in other protein kinases, interacts with an arginine adjacent to the catalytic aspartate but does not participate in interdomain contacts. The interactions between the enzyme and the nucleotide product of its activity, Mg2+/ADP, explain the inhibitory properties of the nucleotides that are observed in kinetic studies.
- Schulze-Gahmen U et al.
- Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
- Proteins. 1995; 22: 378-91
- Display abstract
- Cyclin-dependent kinases (CDKs) are conserved regulators of the eukaryotic cell cycle with different isoforms controlling specific phases of the cell cycle. Mitogenic or growth inhibitory signals are mediated, respectively, by activation or inhibition of CDKs which phosphorylate proteins associated with the cell cycle. The central role of CDKs in cell cycle regulation makes them a potential new target for inhibitory molecules with anti-proliferative and/or anti-neoplastic effects. We describe the crystal structures of the complexes of CDK2 with a weakly specific CDK inhibitor, N6-(delta 2-isopentenyl)adenine, and a strongly specific inhibitor, olomoucine. Both inhibitors are adenine derivatives and bind in the adenine binding pocket of CDK2, but in an unexpected and different orientation from the adenine of the authentic ligand ATP. The N6-benzyl substituent in olomoucine binds outside the conserved binding pocket and is most likely responsible for its specificity. The structural information from the CDK2-olomoucine complex will be useful in directing the search for the next generation inhibitors with improved properties.
- Zhang J, Zhang F, Ebert D, Cobb MH, Goldsmith EJ
- Activity of the MAP kinase ERK2 is controlled by a flexible surface loop.
- Structure. 1995; 3: 299-307
- Display abstract
- BACKGROUND: The mitogen-activated protein (MAP) kinase, ERK2, is a tightly regulated enzyme in the ubiquitous Ras-activated protein kinase cascade. ERK2 is activated by phosphorylation at two sites, Y185 and T183, that lie in the phosphorylation lip at the mouth of the catalytic site. To ascertain the role of these two residues in securing the low-activity conformation of the enzymes we have carried out crystallographic analyses and assays of phosphorylation-site mutants of ERK2. RESULTS: The crystal structures of four mutants, T183E (threonine at residue 183 is replaced by glutamate), Y185E, Y185F and the double mutant T183E/Y185E, were determined. When T183 is replaced by glutamate, few conformational changes are observed. By contrast, when Y185 is replaced by glutamate, 19 residues become disordered, including the entire phosphorylation lip and an adjacent loop. The conservative substitution of phenylalanine for Y185 also induces relatively large conformational changes. A binding site for phosphotyrosine in the active enzyme is putatively identified on the basis of the high-resolution refinement of the structure of wild-type ERK2. CONCLUSIONS: The remarkable disorder observed throughout the phosphorylation lip when Y185 is mutated shows that the stability of the phosphorylation lip is rather low. Therefore, only modest amounts of binding energy will be required to dislodge the lip for phosphorylation, and it is likely that these residues will be involved in conformational changes associated with both with binding to kinases and phosphatases and with activation. Furthermore, the low-activity structure is specifically dependent on Y185, whereas there is no such dependency on T183. Both residues, however, participate in forming the active enzyme, contributing to its tight control.
- Taylor SS, Radzio-Andzelm E
- Three protein kinase structures define a common motif.
- Structure. 1994; 2: 345-55
- Display abstract
- Structural comparisons between cAMP-dependent protein kinase, cyclin-dependent kinase 2 and mitogen-activated protein kinase reveal which features are common to the protein kinase family and which are enzyme-specific.
- Zhang F, Strand A, Robbins D, Cobb MH, Goldsmith EJ
- Atomic structure of the MAP kinase ERK2 at 2.3 A resolution.
- Nature. 1994; 367: 704-11
- Display abstract
- The structure of the MAP kinase ERK2, a ubiquitous protein kinase target for regulation by Ras and Raf, has been solved in its unphosphorylated low-activity conformation to a resolution of 2.3 A. The two domains of unphosphorylated ERK2 are farther apart than in the active conformation of cAMP-dependent protein kinase and the peptide-binding site is blocked by tyrosine 185, one of the two residues that are phosphorylated in the active enzyme. Activation of ERK2 is thus likely to involve both global and local conformational changes.
- Bossemeyer D, Engh RA, Kinzel V, Ponstingl H, Huber R
- Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24).
- EMBO J. 1993; 12: 849-59
- Display abstract
- The crystal structure of the porcine heart catalytic subunit of cAMP-dependent protein kinase in a ternary complex with the MgATP analogue MnAMP-PNP and a pseudosubstrate inhibitor peptide, PKI(5-24), has been solved at 2.0 A resolution from monoclinic crystals of the catalytic subunit isoform CA. The refinement is presently at an R factor of 0.194 and the active site of the molecule is well defined. The glycine-rich phosphate anchor of the nucleotide binding fold motif of the protein kinase is a beta ribbon acting as a flap with conformational flexibility over the triphosphate group. The glycines seem to be conserved to avoid steric clash with ATP. The known synergistic effects of substrate binding can be explained by hydrogen bonds present only in the ternary complex. Implications for the kinetic scheme of binding order are discussed. The structure is assumed to represent a phosphotransfer competent conformation. The invariant conserved residue Asp166 is proposed to be the catalytic base and Lys168 to stabilize the transition state. In some tyrosine kinases Lys168 is functionally replaced by an Arg displaced by two residues in the primary sequence, suggesting invariance in three-dimensional space. The structure supports an in-line transfer with a pentacoordinate transition state at the phosphorus with very few nuclear movements.
- DeBondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH
- Crystal structure of cyclin-dependent kinase 2.
- Nature. 1993; 363: 595-602
- Display abstract
- Cyclin-dependent kinase 2 (CDK2) is a member of a highly conserved family of protein kinases that regulate the eukaryotic cell cycle. The crystal structures of the human CDK2 apoenzyme and its Mg2+ ATP complex have been determined to 2.4 A resolution. The structure is bi-lobate, like that of the cyclic AMP-dependent protein kinase, but contains a unique helix-loop segment that interferes with ATP and protein substrate binding and probably plays a key part in the regulation of all cyclin-dependent kinases.
- Zheng J et al.
- Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor.
- Biochemistry. 1993; 32: 2154-61
- Display abstract
- The structure of a ternary complex of the catalytic subunit of cAMP-dependent protein kinase, MgATP, and a 20-residue inhibitor peptide was determined at a resolution of 2.7 A using the difference Fourier technique starting from the model of the binary complex (Knighton et al., 1991a). The model of the ternary complex was refined using both X-PLOR and TNT to an R factor of 0.212 and 0.224, respectively. The orientation of the nucleotide and the interactions of MgATP with numerous conserved residues at the active site of the enzyme are clearly defined. The unique protein kinase nucleotide binding site consists of a five-stranded antiparallel beta-sheet with the base buried in a hydrophobic site along beta-strands 1 and 2 and fixed by hydrogen bonds to the N6 amino and N7 nitrogens. The small lobe secures the nucleotide via a glycine-rich loop and by ion pairing with Lys72 and Glu91. While the small lobe fixes the nontransferable alpha- and beta-phosphates in this inhibitor complex, the gamma-phosphate is secured by two Mg2+ ions and interacts both directly and indirectly with several residues in the large lobe--Asp184, Asn171, Lys168. Asp166 is positioned to serve as a catalytic base. The structure is correlated with previous chemical evidence, and the features that distinguish this nucleotide binding motif from other nucleotide binding proteins are delineated.
- Knighton DR, Zheng JH, TenEyck LF, Xuong NH, Taylor SS, Sowadski JM
- Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
- Science. 1991; 253: 414-20
- Display abstract
- The structure of a 20-amino acid peptide inhibitor bound to the catalytic subunit of cyclic AMP-dependent protein kinase, and its interactions with the enzyme, are described. The x-ray crystal structure of the complex is the basis of the analysis. The peptide inhibitor, derived from a naturally occurring heat-stable protein kinase inhibitor, contains an amphipathic helix that is followed by a turn and an extended conformation. The extended region occupies the cleft between the two lobes of the enzyme and contains a five-residue consensus recognition sequence common to all substrates and peptide inhibitors of the catalytic subunit. The helical portion of the peptide binds to a hydrophobic groove and conveys high affinity binding. Loops from both domains converge at the active site and contribute to a network of conserved residues at the sites of magnesium adenosine triphosphate binding and catalysis. Amino acids associated with peptide recognition, nonconserved, extend over a large surface area.
- Knighton DR et al.
- Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
- Science. 1991; 253: 407-14
- Display abstract
- The crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase complexed with a 20-amino acid substrate analog inhibitor has been solved and partially refined at 2.7 A resolution to an R factor of 0.212. The magnesium adenosine triphosphate (MgATP) binding site was located by difference Fourier synthesis. The enzyme structure is bilobal with a deep cleft between the lobes. The cleft is filled by MgATP and a portion of the inhibitor peptide. The smaller lobe, consisting mostly of amino-terminal sequence, is associated with nucleotide binding, and its largely antiparallel beta sheet architecture constitutes an unusual nucleotide binding motif. The larger lobe is dominated by helical structure with a single beta sheet at the domain interface. This lobe is primarily involved in peptide binding and catalysis. Residues 40 through 280 constitute a conserved catalytic core that is shared by more than 100 protein kinases. Most of the invariant amino acids in this conserved catalytic core are clustered at the sites of nucleotide binding and catalysis.
- Weber IT, Steitz TA, Bubis J, Taylor SS
- Predicted structures of cAMP binding domains of type I and II regulatory subunits of cAMP-dependent protein kinase.
- Biochemistry. 1987; 26: 343-51
- Display abstract
- The mammalian cAMP-dependent protein kinases have regulatory (R) subunits that show substantial homology in amino acid sequence with the catabolite gene activator protein (CAP), a cAMP-dependent gene regulatory protein from Escherichia coli. Each R subunit has two in-tandem cAMP binding domains, and the structure of each of these domains has been modeled by analogy with the crystal structure of CAP. Both the type I and II regulatory subunits have been considered, so that four cAMP binding domains have been modeled. The binding of cAMP in general is analogous in all the structures and has been correlated with previous results based on photolabeling and binding of cAMP analogues. The model predicts that the first cAMP binding domain correlates with the previously defined fast dissociation site, which preferentially binds N6-substituted analogues of cAMP. The second domain corresponds to the slow dissociation site, which has a preference for C8-substituted analogues. The model also is consistent with cAMP binding in the syn conformation in both sites. Finally, this model has targeted specific regions that are likely to be involved in interdomain contacts. This includes contacts between the two cAMP binding domains as well as contacts with the amino-terminal region of the R subunit and with the catalytic subunit.
Disease (disease genes where sequence variants are found in this domain)

SwissProt sequences and OMIM curated human diseases associated with missense mutations within the S_TKc domain.

Protein	Disease
TGF-beta receptor type-2 precursor (SRS)(SMART)	OMIM:190182: Colon cancer ; Colorectal cancer, hereditary nonpolyposis, type 6 OMIM:114500: Esophageal cancer OMIM:133239:
Phosphorylase b kinase gamma catalytic chain, testis/liver isoform (SRS)(SMART)	OMIM:172471: Glycogenosis, hepatic, autosomal
Rhodopsin kinase precursor (SRS)(SMART)	OMIM:180381: Oguchi disease-2 OMIM:258100:
Tyrosine-protein kinase BTK (SRS)(SMART)	OMIM:300300: Agammaglobulinemia, type 1, X-linked ; ?XLA and isolated growth hormone deficiency OMIM:307200:
Insulin receptor precursor (EC 2.7.10.1) (IR) (CD220 antigen) [Contains: Insulin receptor subunit alpha; Insulin receptor subunit beta] (SRS)(SMART)	OMIM:147670: Leprechaunism OMIM:246200: Rabson-Mendenhall syndrome OMIM:262190: Diabetes mellitus, insulin-resistant, with acanthosis nigricans
Tyrosine-protein kinase ZAP-70 (SRS)(SMART)	OMIM:176947: Selective T-cell defect
Serine/threonine-protein kinase receptor R3 precursor (SRS)(SMART)	OMIM:601284: Hereditary hemorrhagic telangiectasia-2 OMIM:600376:
High affinity nerve growth factor receptor precursor (SRS)(SMART)	OMIM:191315: Insensitivity to pain, congenital, with anhidrosis OMIM:256800: Medullary thyroid carcinoma, familial OMIM:155240:
Retinal guanylyl cyclase 1 precursor (SRS)(SMART)	OMIM:601777: Cone dystrophy, progressive OMIM:600179: Leber congenital amaurosis, type I OMIM:204000: Cone-rod dystrophy 6 OMIM:601777:
Ribosomal protein S6 kinase alpha-3 (SRS)(SMART)	OMIM:300075: Coffin-Lowry syndrome OMIM:303600: Mental retardation, X-linked nonspecific, type 19
Protein kinase C gamma type (SRS)(SMART)	OMIM:176980: PROTEIN KINASE C, GAMMA; PRKCG
Fibroblast growth factor receptor 3 precursor (SRS)(SMART)	OMIM:134934: Achondroplasia OMIM:100800: Hypochondroplasia OMIM:146000: Thanatophoric dysplasia, types I and II OMIM:187600: Crouzon syndrome with acanthosis nigricans ; Muencke syndrome OMIM:602849: OMIM:600593: Craniosynostosis, Adelaide type
Proto-oncogene tyrosine-protein kinase receptor ret precursor (SRS)(SMART)	OMIM:164761: Multiple endocrine neoplasia IIA OMIM:171400: Medullary thyroid carcinoma OMIM:155240: Multiple endocrine neoplasia IIB OMIM:162300: Hirschsprung disease OMIM:142623: OMIM:188550: Thyroid papillary carcinoma
Serine/threonine-protein kinase 11 (SRS)(SMART)	OMIM:602216: Peutz-Jeghers syndrome OMIM:175200:
Cell division protein kinase 4 (SRS)(SMART)	OMIM:123829: Melanoma
Angiopoietin-1 receptor precursor (SRS)(SMART)	OMIM:600221: Venous malformations, multiple cutaneous and mucosal OMIM:600195:
Hepatocyte growth factor receptor precursor (SRS)(SMART)	OMIM:164860: Renal cell carcinoma, papillary, familial and sporadic OMIM:605074: Hepatocellular carcinoma, childhood type OMIM:114550:
Mast/stem cell growth factor receptor precursor (SRS)(SMART)	OMIM:164920: Piebaldism ; Mast cell leukemia ; Mastocytosis with associated hematologic disorder ; Germ cell tumors OMIM:273300:

Metabolism (metabolic pathways involving proteins which contain this domain)

Click the image to view the interactive version of the map in iPath

% proteins involved	KEGG pathway ID	Description
7.46	map04010	MAPK signaling pathway
3.88	map04912	GnRH signaling pathway
3.73	map04012	ErbB signaling pathway
3.58	map04910	Insulin signaling pathway
3.55	map04914	Progesterone-mediated oocyte maturation
3.54	map04510	Focal adhesion
2.72	map04720	Long-term potentiation
2.65	map04620	Toll-like receptor signaling pathway
2.62	map04310	Wnt signaling pathway
2.62	map04540	Gap junction
2.57	map04664	Fc epsilon RI signaling pathway
2.56	map04370	VEGF signaling pathway
2.53	map04150	mTOR signaling pathway
2.40	map04916	Melanogenesis
2.23	map04810	Regulation of actin cytoskeleton
2.10	map05214	Glioma
2.06	map04020	Calcium signaling pathway
2.04	map05223	Non-small cell lung cancer
2.01	map00632	Benzoate degradation via CoA ligation
2.01	map00562	Inositol phosphate metabolism
2.00	map05211	Renal cell carcinoma
1.97	map04530	Tight junction
1.92	map04360	Axon guidance
1.70	map05215	Prostate cancer
1.67	map05221	Acute myeloid leukemia
1.55	map04110	Cell cycle
1.52	map05212	Pancreatic cancer
1.51	map05213	Endometrial cancer
1.51	map04650	Natural killer cell mediated cytotoxicity
1.48	map05210	Colorectal cancer
1.48	map04730	Long-term depression
1.46	map05120	Epithelial cell signaling in Helicobacter pylori infection
1.42	map04670	Leukocyte transendothelial migration
1.39	map04920	Adipocytokine signaling pathway
1.36	map05220	Chronic myeloid leukemia
1.35	map04660	T cell receptor signaling pathway
1.29	map05218	Melanoma
1.24	map04740	Olfactory transduction
1.18	map05219	Bladder cancer
1.02	map04210	Apoptosis
1.01	map04520	Adherens junction
1.01	map04350	TGF-beta signaling pathway
0.92	map04340	Hedgehog signaling pathway
0.87	map04115	p53 signaling pathway
0.81	map04111	Cell cycle - yeast
0.80	map05216	Thyroid cancer
0.77	map04930	Type II diabetes mellitus
0.70	map04320	Dorso-ventral axis formation
0.68	map05222	Small cell lung cancer
0.65	map04140	Regulation of autophagy
0.61	map04742	Taste transduction
0.59	map04662	B cell receptor signaling pathway
0.46	map04630	Jak-STAT signaling pathway
0.43	map04070	Phosphatidylinositol signaling system
0.31	map05217	Basal cell carcinoma
0.19	map03320	PPAR signaling pathway
0.18	map05010	Alzheimer's disease
0.09	map04120	Ubiquitin mediated proteolysis
0.03	map00540	Lipopolysaccharide biosynthesis

This information is based on mapping of SMART genomic protein database to KEGG orthologous groups. Percentage points are related to the number of proteins with S_TKc domain which could be assigned to a KEGG orthologous group, and not all proteins containing S_TKc domain. Please note that proteins can be included in multiple pathways, ie. the numbers above will not always add up to 100%.

Structure (3D structures containing this domain)

3D Structures of S_TKc domains in PDB

PDB code	Main view	Title
1a06		Calmodulin-dependent protein kinase from rat
1a9u		The complex structure of the map kinase p38/sb203580
1apm		2.0 angstrom refined crystal structure of the catalytic subunit of camp-dependent protein kinase complexed with a peptide inhibitor and detergent
1aq1		Human cyclin dependent kinase 2 complexed with the inhibitor staurosporine
1atp		2.2 angstrom refined crystal structure of the catalytic subunit of camp-dependent protein kinase complexed with mnatp and a peptide inhibitor
1b38		Human cyclin-dependent kinase 2
1b39		Human cyclin-dependent kinase 2 phosphorylated on thr 160
1bi7		Mechanism of g1 cyclin dependent kinase inhibition from the structure of the cdk6-p16ink4a tumor suppressor complex
1bi8		Mechanism of g1 cyclin dependent kinase inhibition from the structures cdk6-p19ink4d inhibitor complex
1bkx		A binary complex of the catalytic subunit of camp-dependent protein kinase and adenosine further defines conformational flexibility
1bl6		The complex structure of the map kinase p38/sb216995
1bl7		The complex structure of the map kinase p38/sb220025
1blx		P19ink4d/cdk6 complex
1bmk		The complex structure of the map kinase p38/sb218655
1buh		Crystal structure of the human cdk2 kinase complex with cell cycle-regulatory protein ckshs1
1bx6		Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of camp- dependent protein kinase
1cdk		Camp-dependent protein kinase catalytic subunit (e.c.2.7.1.37) (protein kinase a) complexed with protein kinase inhibitor peptide fragment 5-24 (pki(5-24) isoelectric variant ca) and mn2+ adenylyl imidodiphosphate (mnamp-pnp) at ph 5.6 and 7c and 4c
1ckp		Human cyclin dependent kinase 2 complexed with the inhibitor purvalanol b
1cm8		Phosphorylated map kinase p38-gamma
1cmk		Crystal structures of the myristylated catalytic subunit of camp-dependent protein kinase reveal open and closed conformations
1ctp		Structure of the mammalian catalytic subunit of camp- dependent protein kinase and an inhibitor peptide displays an open conformation
1daw		Crystal structure of a binary complex of protein kinase ck2 (alpha-subunit) and mg-amppnp
1day		Crystal structure of a binary complex of protein kinase ck2 (alpha-subunit) and mg-gmppnp
1di8		The structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline
1di9		The structure of p38 mitogen-activated protein kinase in complex with 4-[3-methylsulfanylanilino]-6,7- dimethoxyquinazoline
1dm2		Human cyclin-dependent kinase 2 complexed with the inhibitor hymenialdisine
1ds5		Dimeric crystal structure of the alpha subunit in complex with two beta peptides mimicking the architecture of the tetrameric protein kinase ck2 holoenzyme.
1e1v		Human cyclin dependent kinase 2 complexed with the inhibitor nu2058
1e1x		Human cyclin dependent kinase 2 complexed with the inhibitor nu6027
1e9h		Thr 160 phosphorylated cdk2-human cyclin a3 complex with the inhibitor indirubin-5-sulphonate bound
1erk		Structure of signal-regulated kinase
1f0q		Crystal structure of the alpha subunit of protein kinase ck2 in complex with the nucleotide competitive inhibitor emodin
1f3m		Crystal structure of human serine/threonine kinase pak1
1f5q		Crystal structure of murine gamma herpesvirus cyclin complexed to human cyclin dependent kinase 2
1fin		Cyclin a-cyclin-dependent kinase 2 complex
1fmo		Crystal structure of a polyhistidine-tagged recombinant catalytic subunit of camp-dependent protein kinase complexed with the peptide inhibitor pki(5-24) and adenosine
1fot		Structure of the unliganded camp-dependent protein kinase catalytic subunit from saccharomyces cerevisiae
1fq1		Crystal structure of kinase associated phosphatase (kap) in complex with phospho-cdk2
1fvt		The structure of cyclin-dependent kinase 2 (cdk2) in complex with an oxindole inhibitor
1fvv		The structure of cdk2/cyclin a in complex with an oxindole inhibitor
1g3n		Structure of a p18(ink4c)-cdk6-k-cyclin ternary complex
1g5s		Crystal structure of human cyclin dependent kinase 2 (cdk2) in complex with the inhibitor h717
1gih		Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
1gii		Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
1gij		Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
1gng		Glycogen synthase kinase-3 beta (gsk3) complex with frattide peptide
1gol		Coordinates of rat map kinase erk2 with an arginine mutation at position 52
1gy3		Pcdk2/cyclin a in complex with mgadp, nitrate and peptide substrate
1gz8		Human cyclin dependent kinase 2 complexed with the inhibitor 2-amino-6-(3'-methyl-2'-oxo)butoxypurine
1gzk		Molecular mechanism for the regulation of protein kinase b/ akt by hydrophobic motif phosphorylation
1gzn		Structure of pkb kinase domain
1gzo		Structure of protein kinase b unphosphorylated
1h00		Cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
1h01		Cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor
1h07		Cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
1h08		Cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor
1h0v		Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[(r)-pyrrolidino-5'-yl]methoxypurine
1h0w		Human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[cyclohex-3-enyl]methoxypurine
1h1p		Structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu2058
1h1q		Structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6094
1h1r		Structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6086
1h1s		Structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6102
1h1w		High resolution crystal structure of the human pdk1 catalytic domain
1h24		Cdk2/cyclin a in complex with a 9 residue recruitment peptide from e2f
1h25		Cdk2/cyclin a in complex with an 11-residue recruitment peptide from retinoblastoma-associated protein
1h26		Cdk2/cyclin a in complex with an 11-residue recruitment peptide from p53
1h27		Cdk2/cyclin a in complex with an 11-residue recruitment peptide from p27
1h28		Cdk2/cyclin a in complex with an 11-residue recruitment peptide from p107
1h4l		Structure and regulation of the cdk5-p25(nck5a) complex
1h8f		Glycogen synthase kinase 3 beta.
1hck		Human cyclin-dependent kinase 2
1hcl		Human cyclin-dependent kinase 2
1how		The x-ray crystal structure of sky1p, an sr protein kinase in yeast
1i09		Structure of glycogen synthase kinase-3 (gsk3b)
1ia8		The 1.7 a crystal structure of human cell cycle checkpoint kinase chk1
1ian		Human p38 map kinase inhibitor complex
1ig1		1.8a x-ray structure of ternary complex of a catalytic domain of death-associated protein kinase with atp analogue and mn.
1j1b		Binary complex structure of human tau protein kinase i with amppnp
1j1c		Binary complex structure of human tau protein kinase i with adp
1j3h		Crystal structure of apoenzyme camp-dependent protein kinase catalytic subunit
1j91		Crystal structure of z. mays ck2 kinase alpha subunit in complex with the atp-competitive inhibitor 4,5,6,7- tetrabromobenzotriazole
1jam		Crystal structure of apo-form of z. mays ck2 protein kinase alpha subunit
1jbp		Crystal structure of the catalytic subunit of camp- dependent protein kinase complexed with a substrate peptide, adp and detergent
1jkk		2.4a x-ray structure of ternary complex of a catalytic domain of death-associated protein kinase with atp analogue and mg.
1jkl		1.6a x-ray structure of binary complex of a catalytic domain of death-associated protein kinase with atp analogue
1jks		1.5a x-ray structure of apo form of a catalytic domain of death-associated protein kinase
1jkt		Tetragonal crystal form of a catalytic domain of death- associated protein kinase
1jlu		Crystal structure of the catalytic subunit of camp- dependent protein kinase complexed with a phosphorylated substrate peptide and detergent
1jnk		The c-jun n-terminal kinase (jnk3s) complexed with mgamp-pnp
1jow		Crystal structure of a complex of human cdk6 and a viral cyclin
1jst		Phosphorylated cyclin-dependent kinase-2 bound to cyclin a
1jsu		P27(kip1)/cyclin a/cdk2 complex
1jsv		The structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[(6-amino-4-pyrimidinyl) amino]benzenesulfonamide
1jvp		Crystal structure of human cdk2 (unphosphorylated) in complex with pkf049-365
1jwh		Crystal structure of human protein kinase ck2 holoenzyme
1ke5		Cdk2 complexed with n-methyl-4-{[(2-oxo-1,2-dihydro-3h- indol-3-ylidene)methyl]amino}benzenesulfonamide
1ke6		Cyclin-dependent kinase 2 (cdk2) complexed with n-methyl-{4- [2-(7-oxo-6,7-dihydro-8h-[1,3]thiazolo[5,4-e]indol-8- ylidene)hydrazino]phenyl}methanesulfonamide
1ke7		Cyclin-dependent kinase 2 (cdk2) complexed with 3-{[(2,2- dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5- (1,3-oxazol-5-yl)-1,3-dihydro-2h-indol-2-one
1ke8		Cyclin-dependent kinase 2 (cdk2) complexed with 4-{[(2-oxo- 1,2-dihydro-3h-indol-3-ylidene)methyl]amino}-n-(1,3- thiazol-2-yl)benzenesulfonamide
1ke9		Cyclin-dependent kinase 2 (cdk2) complexed with 3-{[4- ({[amino(imino)methyl]aminosulfonyl)anilino]methylene}-2- oxo-2,3-dihydro-1h-indole
1koa		Twitchin kinase fragment (c.elegans), autoregulated protein kinase and immunoglobulin domains
1kob		Twitchin kinase fragment (aplysia), autoregulated protein kinase domain
1kv1		P38 map kinase in complex with inhibitor 1
1kv2		Human p38 map kinase in complex with birb 796
1kwp		Crystal structure of mapkap2
1l3r		Crystal structure of a transition state mimic of the catalytic subunit of camp-dependent protein kinase
1lew		Crystal structure of map kinase p38 complexed to the docking site on its nuclear substrate mef2a
1lez		Crystal structure of map kinase p38 complexed to the docking site on its activator mkk3b
1lp4		Crystal structure of a binary complex of the catalytic subunit of protein kinase ck2 with mg-amppnp
1lpu		Low temperature crystal structure of the apo-form of the catalytic subunit of protein kinase ck2 from zea mays
1lr4		Room temperature crystal structure of the apo-form of the catalytic subunit of protein kinase ck2 from zea mays
1m2p		Crystal structure of 1,8-di-hydroxy-4-nitro- anthraquinone/ck2 kinase complex
1m2q		Crystal structure of 1,8-di-hydroxy-4-nitro-xanten-9- one/ck2 kinase complex
1m2r		Crystal structure of 5,8-di-amino-1,4-di-hydroxy- anthraquinone/ck2 kinase complex
1m7q		Crystal structure of p38 map kinase in complex with a dihydroquinazolinone inhibitor
1mq4		Crystal structure of aurora-a protein kinase
1mru		Intracellular ser/thr protein kinase domain of mycobacterium tuberculosis pknb.
1mrv		Crystal structure of an inactive akt2 kinase domain
1mry		Crystal structure of an inactive akt2 kinase domain
1muo		Crystal structure of aurora-2, an oncogenic serine- threonine kinase
1na7		Crystal structure of the catalytic subunit of human protein kinase ck2
1nvq		The complex structure of checkpoint kinase chk1/ucn-01
1nvr		The complex structure of checkpoint kinase chk1/staurosporine
1nvs		The complex structure of checkpoint kinase chk1/sb218078
1nxk		Crystal structure of staurosporine bound to map kap kinase 2
1ny3		Crystal structure of adp bound to map kap kinase 2
1o6k		Structure of activated form of pkb kinase domain s474d with gsk3 peptide and amp-pnp
1o6l		Crystal structure of an activated akt/protein kinase b (pkb- pif chimera) ternary complex with amp-pnp and gsk3 peptide
1o6y		Catalytic domain of pknb kinase from mycobacterium tuberculosis
1o9u		Glycogen synthase kinase 3 beta complexed with axin peptide
1ob3		Structure of p. falciparum pfpk5
1ogu		Structure of human thr160-phospho cdk2/cyclin a complexed with a 2-arylamino-4-cyclohexylmethyl-5-nitroso-6- aminopyrimidine inhibitor
1oi9		Structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
1oiq		Imidazopyridines: a potent and selective class of cyclin- dependent kinase inhibitors identified through structure- based hybridisation
1oir		Imidazopyridines: a potent and selective class of cyclin- dependent kinase inhibitors identified through structure- based hybridisation
1oit		Imidazopyridines: a potent and selective class of cyclin- dependent kinase inhibitors identified through structure- based hybridisation
1oiu		Structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
1oiy		Structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor
1okv		Cyclin a binding groove inhibitor h-arg-arg-leu-ile-phe-nh2
1okw		Cyclin a binding groove inhibitor ac-arg-arg-leu-asn-(m-cl- phe)-nh2
1oky		Structure of human pdk1 kinase domain in complex with staurosporine
1okz		Structure of human pdk1 kinase domain in complex with ucn-01
1ol1		Cyclin a binding groove inhibitor h-cit-cit-leu-ile-(p-f- phe)-nh2
1ol2		Cyclin a binding groove inhibitor h-arg-arg-leu-asn-(p-f- phe)-nh2
1ol5		Structure of aurora-a 122-403, phosphorylated on thr287, thr288 and bound to tpx2 1-43
1ol6		Structure of unphosphorylated d274n mutant of aurora-a
1ol7		Structure of human aurora-a 122-403 phosphorylated on thr287, thr288
1om1		Crystal structure of maize ck2 alpha in complex with iqa
1omw		Crystal structure of the complex between g protein-coupled receptor kinase 2 and heterotrimeric g protein beta 1 and gamma 2 subunits
1ouk		The structure of p38 alpha in complex with a pyridinylimidazole inhibitor
1ouy		The structure of p38 alpha in complex with a dihydropyrido- pyrimidine inhibitor
1ove		The structure of p38 alpha in complex with a dihydroquinolinone
1oz1		P38 mitogen-activated kinase in complex with 4-azaindole inhibitor
1p2a		The structure of cyclin dependent kinase 2 (ckd2) with a trisubstituted naphthostyril inhibitor
1p38		The structure of the map kinase p38 at 2.1 angstoms resolution
1p4f		Death associated protein kinase catalytic domain with bound inhibitor fragment
1p5e		The strucure of phospho-cdk2/cyclin a in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazole (tbs)
1pf8		Crystal structure of human cyclin-dependent kinase 2 complexed with a nucleoside inhibitor
1phk		Two structures of the catalytic domain of phosphorylase, kinase: an active protein kinase complexed with nucleotide, substrate-analogue and product
1pjk		Crystal structure of a c-terminal deletion mutant of human protein kinase ck2 catalytic subunit
1pkd		The crystal structure of ucn-01 in complex with phospho- cdk2/cyclin a
1pme		Structure of penta mutant human erk2 map kinase complexed with a specific inhibitor of human p38 map kinase
1pmn		Crystal structure of jnk3 in complex with an imidazole- pyrimidine inhibitor
1pmq		The structure of jnk3 in complex with an imidazole- pyrimidine inhibitor
1pmu		The crystal structure of jnk3 in complex with a phenantroline inhibitor
1pmv		The structure of jnk3 in complex with a dihydroanthrapyrazole inhibitor
1pw2		Apo structure of human cyclin-dependent kinase 2
1pxi		Human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2- ylamine
1pxj		Human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine
1pxk		Human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-yl]- n'-hydroxyiminoformamide
1pxl		Human cyclin dependent kinase 2 complexed with the inhibitor [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- (4-trifluoromethyl-phenyl)-amine
1pxm		Human cyclin dependent kinase 2 complexed with the inhibitor 3-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2- ylamino]-phenol
1pxn		Human cyclin dependent kinase 2 complexed with the inhibitor 4-[4-(4-methyl-2-methylamino-thiazol-5-yl)- pyrimidin-2-ylamino]-phenol
1pxo		Human cyclin dependent kinase 2 complexed with the inhibitor [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2- yl]-(3-nitro-phenyl)-amine
1pxp		Human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]- n',n'-dimethyl-benzene-1,4-diamine
1pye		Crystal structure of cdk2 with inhibitor
1pyx		Gsk-3 beta complexed with amp-pnp
1q24		Pka double mutant model of pkb in complex with mgatp
1q3d		Gsk-3 beta complexed with staurosporine
1q3w		Gsk-3 beta complexed with alsterpaullone
1q41		Gsk-3 beta complexed with indirubin-3'-monoxime
1q4l		Gsk-3 beta complexed with inhibitor i-5
1q5k		Crystal structure of glycogen synthase kinase 3 in complexed with inhibitor
1q61		Pka triple mutant model of pkb
1q62		Pka double mutant model of pkb
1q8t		The catalytic subunit of camp-dependent protein kinase (pka) in complex with rho-kinase inhibitor y-27632
1q8u		The catalytic subunit of camp-dependent protein kinase in complex with rho-kinase inhibitor h-1152p
1q8w		The catalytic subunit of camp-dependent protein kinase in complex with rho-kinase inhibitor fasudil (ha-1077)
1q8y		The structure of the yeast sr protein kinase, sky1p, with bound adp
1q8z		The apoenzyme structure of the yeast sr protein kinase, sky1p
1q97		The structure of the saccharomyces cerevisiae sr protein kinase, sky1p, with bound atp
1q99		Crystal structure of the saccharomyces cerevisiae sr protein kinsae, sky1p, complexed with the non-hydrolyzable atp analogue, amp-pnp
1ql6		The catalytic mechanism of phosphorylase kinase probed by mutational studies
1qmz		Phosphorylated cdk2-cyclyin a-substrate peptide complex
1r0e		Glycogen synthase kinase-3 beta in complex with 3-indolyl-4- arylmaleimide inhibitor
1r39		The structure of p38alpha
1r3c		The structure of p38alpha c162s mutant
1r78		Cdk2 complex with a 4-alkynyl oxindole inhibitor
1rdq		Hydrolysis of atp in the crystal of y204a mutant of camp- dependent protein kinase
1re8		Crystal structure of camp-dependent protein kinase complexed with balanol analog 2
1rej		Crystal structure of camp-dependent protein kinase complexed with balanol analog 1
1rek		Crystal structure of camp-dependent protein kinase complexed with balanol analog 8
1s9i		X-ray structure of the human mitogen-activated protein kinase kinase 2 (mek2)in a complex with ligand and mgatp
1s9j		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a complex with ligand and mgatp
1smh		Protein kinase a variant complex with completely ordered n- terminal helix
1stc		Camp-dependent protein kinase, alpha-catalytic subunit in complex with staurosporine
1sve		Crystal structure of protein kinase a in complex with azepane derivative 1
1svg		Crystal structure of protein kinase a in complex with azepane derivative 4
1svh		Crystal structure of protein kinase a in complex with azepane derivative 8
1syk		Crystal structure of e230q mutant of camp-dependent protein kinase reveals unexpected apoenzyme conformation
1szm		Dual binding mode of bisindolylmaleimide 2 to protein kinase a (pka)
1tki		Autoinhibited serine kinase domain of the giant muscle protein titin
1tvo		The structure of erk2 in complex with a small molecule inhibitor
1u5q		Crystal structure of the tao2 kinase domain: activation and specifity of a ste20p map3k
1u5r		Crystal structure of the tao2 kinase domain: activation and specifity of a ste20p map3k
1ua2		Crystal structure of human cdk7
1ukh		Structural basis for the selective inhibition of jnk1 by the scaffolding protein jip1 and sp600125
1uki		Structural basis for the selective inhibition of jnk1 by the scaffolding protein jip1 and sp600125
1ung		Structural mechanism for the inhibition of cdk5-p25 by roscovitine, aloisine and indirubin.
1unh		Structural mechanism for the inhibition of cdk5-p25 by roscovitine, aloisine and indirubin.
1unl		Structural mechanism for the inhibition of cd5-p25 from the roscovitine, aloisine and indirubin.
1urc		Cyclin a binding groove inhibitor ace-arg-lys-leu-phe-gly
1urw		Cdk2 in complex with an imidazo[1,2-b]pyridazine
1uu3		Structure of human pdk1 kinase domain in complex with ly333531
1uu7		Structure of human pdk1 kinase domain in complex with bim-2
1uu8		Structure of human pdk1 kinase domain in complex with bim-1
1uu9		Structure of human pdk1 kinase domain in complex with bim-3
1uv5		Glycogen synthase kinase 3 beta complexed with 6- bromoindirubin-3'-oxime
1uvr		Structure of human pdk1 kinase domain in complex with bim-8
1v0b		Crystal structure of the t198a mutant of pfpk5
1v0o		Structure of p. falciparum pfpk5-indirubin-5-sulphonate ligand complex
1v0p		Structure of p. falciparum pfpk5-purvalanol b ligand complex
1v1k		Cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor
1veb		Crystal structure of protein kinase a in complex with azepane derivative 5
1vyw		Structure of cdk2/cyclin a with pnu-292137
1vyz		Structure of cdk2 complexed with pnu-181227
1vzo		The structure of the n-terminal kinase domain of msk1 reveals a novel autoinhibitory conformation for a dual kinase protein
1w0x		Crystals structure of human cdk2 in complex with the inhibitor olomoucine.
1w7h		P38 kinase crystal structure in complex with small molecule inhibitor
1w82		P38 kinase crystal structure in complex with small molecule inhibitor
1w83		P38 kinase crystal structure in complex with small molecule inhibitor
1w84		P38 kinase crystal structure in complex with small molecule inhibitor
1w8c		Co-crystal structure of 6-cyclohexylmethoxy-8-isopropyl-9h- purin-2-ylamine and monomeric cdk2
1w98		The structural basis of cdk2 activation by cyclin e
1wbn		Fragment based p38 inhibitors
1wbo		Fragment based p38 inhibitors
1wbs		Identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation.
1wbt		Identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation.
1wbv		Identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation.
1wbw		Identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation.
1wcc		Screening for fragment binding by x-ray crystallography
1wfc		Structure of apo, unphosphorylated, p38 mitogen activated protein kinase p38 (p38 map kinase) the mammalian homologue of the yeast hog1 protein
1wmk		Human death-associated kinase drp-1, mutant s308d d40
1wvw		Crystal structures of kinase domain of dap kinase in complex with small molecular inhibitors
1wvx		Crystal structures of kinase domain of dap kinase in complex with small molecular inhibitors
1wvy		Crystal structures of kinase domain of dap kinase in complex with small molecular inhibitors
1wzy		Crystal structure of human erk2 complexed with a pyrazolopyridazine derivative
1xh4		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
1xh5		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
1xh6		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
1xh7		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
1xh8		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
1xh9		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
1xha		Crystal structures of protein kinase b selective inhibitors in complex with protein kinase a and mutants
1xjd		Crystal structure of pkc-theta complexed with staurosporine at 2a resolution
1xo2		Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin
1xqz		Crystal structure of hpim-1 kinase at 2.1 a resolution
1xr1		Crystal structure of hpim-1 kinase in complex with amp-pnp at 2.1 a resolution
1xws		Crystal structure of the human pim1 kinase domain
1y8g		Catalytic and ubiqutin-associated domains of mark2/par-1: inactive double mutant with selenomethionine
1y8y		Crystal structure of human cdk2 complexed with a pyrazolo[1, 5-a]pyrimidine inhibitor
1y91		Crystal structure of human cdk2 complexed with a pyrazolo[1, 5-a]pyrimidine inhibitor
1ydr		Structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h7 protein kinase inhibitor 1-(5- isoquinolinesulfonyl)-2-methylpiperazine
1yds		Structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h8 protein kinase inhibitor [n-(2- methylamino)ethyl]-5-isoquinolinesulfonamide
1ydt		Structure of camp-dependent protein kinase, alpha-catalytic subunit in complex with h89 protein kinase inhibitor n-[2- (4-bromocinnamylamino)ethyl]-5-isoquinoline
1yhs		Crystal structure of pim-1 bound to staurosporine
1yhv		Crystal structure of pak1 kinase domain with two point mutations (k299r, t423e)
1yhw		Crystal structure of pak1 kinase domain with one point mutations (k299r)
1yi3		Crystal structure of pim-1 bound to ly294002
1yi4		Structure of pim-1 bound to adenosine
1ykr		Crystal structure of cdk2 with an aminoimidazo pyridine inhibitor
1ym7		G protein-coupled receptor kinase 2 (grk2)
1yqj		Crystal structure of p38 alpha in complex with a selective pyridazine inhibitor
1yrp		Catalytic domain of human zip kinase phosphorylated at thr265
1yw2		Mutated mus musculus p38 kinase (mp38)
1ywr		Crystal structure analysis of inactive p38 kinase domain in complex with a monocyclic pyrazolone inhibitor
1ywv		Crystal structures of proto-oncogene kinase pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma
1yxs		Crystal structure of kinase pim1 with p123m mutation
1yxt		Crystal structure of kinase pim1 in complex with amppnp
1yxu		Crystal structure of kinase pim1 in complex with amp
1yxv		Crystal structure of kinase pim1 in complex with 3,4- dihydroxy-1-methylquinolin-2(1h)-one
1yxx		Crystal structure of kinase pim1 in complex with (3e)-3-[(4- hydroxyphenyl)imino]-1h-indol-2(3h)-one
1z57		Crystal structure of human clk1 in complex with 10z- hymenialdisine
1z5m		Crystal structure of n1-[3-[[5-bromo-2-[[3-[(1- pyrrolidinylcarbonyl)amino]phenyl]amino]-4- pyrimidinyl]amino]propyl]-2,2-dimethylpropanediamide complexed with human pdk1
1z9x		Human drp-1 kinase, w305s s308a d40 mutant, crystal form with 3 monomers in the asymmetric unit
1zlt		Crystal structure of chk1 complexed with a hymenaldisine analog
1zmu		Catalytic and ubiqutin-associated domains of mark2/par-1: wild type
1zmv		Catalytic and ubiqutin-associated domains of mark2/par-1: k82r mutant
1zmw		Catalytic and ubiqutin-associated domains of mark2/par-1: t208a/s212a inactive double mutant
1zoe		Crystal structure of protein kinase ck2 in complex with tbb- derivatives inhibitors
1zog		Crystal structure of protein kinase ck2 in complex with tbb- derivatives
1zoh		Crystal structure of protein kinase ck2 in complex with tbb- derivatives inhibitors
1zrz		Crystal structure of the catalytic domain of atypical protein kinase c-iota
1zws		Crystal structure of the catalytic domain of human drp-1 kinase
1zxe		Crystal structure of eif2alpha protein kinase gcn2: d835n inactivating mutant in apo form
1zy4		Crystal structure of eif2alpha protein kinase gcn2: r794g hyperactivating mutant in apo form.
1zy5		Crystal structure of eif2alpha protein kinase gcn2: r794g hyperactivating mutant complexed with amppnp.
1zyc		Crystal structure of eif2alpha protein kinase gcn2: wild- type in apo form.
1zyd		Crystal structure of eif2alpha protein kinase gcn2: wild- type complexed with atp.
1zyj		Human p38 map kinase in complex with inhibitor 1a
1zys		Co-crystal structure of checkpoint kinase chk1 with a pyrrolo-pyridine inhibitor
1zz2		Two classes of p38alpha map kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes
1zzl		Crystal structure of p38 with triazolopyridine
2a0c		Human cdk2 in complex with olomoucine ii, a novel 2,6,9- trisubstituted purine cyclin-dependent kinase inhibitor
2a27		Human drp-1 kinase, w305s s308a d40 mutant, crystal form with 8 monomers in the asymmetric unit
2a2a		High-resolution crystallographic analysis of the autoinhibited conformation of a human death-associated protein kinase
2a4l		Human cyclin-dependent kinase 2 in complex with roscovitine
2ac3		Structure of human mnk2 kinase domain
2ac5		Structure of human mnk2 kinase domain mutant d228g
2acx		Crystal structure of g protein coupled receptor kinase 6 bound to amppnp
2ayp		Crystal structure of chk1 with an indol inhibitor
2b1p		Inhibitor complex of jnk3
2b52		Human cyclin dependent kinase 2 (cdk2) complexed with dph-
2b53		Human cyclin dependent kinase 2 (cdk2) complexed with din-
2b54		Human cyclin dependent kinase 2 (ckd2)complexed with din-
2b55		Human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole din-101312
2b9f		Crystal structure of non-phosphorylated fus3
2b9h		Crystal structure of fus3 with a docking motif from ste7
2b9i		Crystal structure of fus3 with a docking motif from msg5
2b9j		Crystal structure of fus3 with a docking motif from far1
2baj		P38alpha bound to pyrazolourea
2bak		P38alpha map kinase bound to mpaq
2bal		P38alpha map kinase bound to pyrazoloamine
2baq		P38alpha bound to ro3201195
2bcj		Crystal structure of g protein-coupled receptor kinase 2 in complex with galpha-q and gbetagamma subunits
2bdw		Crystal structure of the auto-inhibited kinase domain of calcium/calmodulin activated kinase ii
2bfx		Mechanism of aurora-b activation by incenp and inhibition by hesperidin.
2bfy		Complex of aurora-b with incenp and hesperidin.
2bhe		Human cyclin dependent protein kinase 2 in complex with the inhibitor 5-bromo-indirubine
2bhh		Human cyclin dependent protein kinase 2 in complex with the inhibitor 4-hydroxypiperindinesulfonyl-indirubine
2bik		Human pim1 phosphorylated on ser261
2bil		The human protein kinase pim1 in complex with its consensus peptide pimtide
2biy		Structure of pdk1-s241a mutant kinase domain
2bkz		Structure of cdk2-cyclin a with pha-404611
2bmc		Aurora-2 t287d t288d complexed with pha-680632
2bpm		Structure of cdk2-cyclin a with pha-630529
2br1		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
2brb		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
2brg		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
2brh		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
2brm		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
2brn		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
2bro		Structure-based design of novel chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity
2btr		Structure of cdk2 complexed with pnu-198873
2bts		Structure of cdk2 complexed with pnu-230032
2bva		Crystal structure of the human p21-activated kinase 4
2bzh		Crystal structure of the human pim1 in complex with a ruthenium organometallic ligand ru1
2bzi		Crystal structure of the human pim1 in complex with a ruthenium organometallic ligand ru2
2bzj		Crystal structure of the human pim1 in complex with a ruthenium organometallic ligand ru3
2bzk		Crystal structure of the human pim1 in complex with amppnp and pimtide
2c1a		Structure of camp-dependent protein kinase complexed with isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy) ethylamino)ethyl)amide
2c1b		Structure of camp-dependent protein kinase complexed with (4r,2s)-5'-(4-(4-chlorobenzyloxy)pyrrolidin-2- ylmethanesulfonyl)isoquinoline
2c30		Crystal structure of the human p21-activated kinase 6
2c3i		Crystal structure of human pim1 in complex with imidazopyridazin i
2c3j		Identification of a buried pocket for potent and selective inhibition of chk1: prediction and verification
2c3k		Identification of a buried pocket for potent and selective inhibition of chk1: prediction and verification
2c3l		Identification of a buried pocket for potent and selective inhibition of chk1: prediction and verification
2c4g		Structure of cdk2-cyclin a with pha-533514
2c5n		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
2c5o		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
2c5v		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
2c5x		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
2c5y		Differential binding of inhibitors to active and inactive cdk2 provides insights for drug design
2c68		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
2c69		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
2c6d		Aurora a kinase activated mutant (t287d) in complex with adpnp
2c6e		Aurora a kinase activated mutant (t287d) in complex with a 5-aminopyrimidinyl quinazoline inhibitor
2c6i		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
2c6k		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
2c6l		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
2c6m		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
2c6o		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
2c6t		Crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor
2cch		The crystal structure of cdk2 cyclin a in complex with a substrate peptide derived from cdc modified with a gamma- linked atp analogue
2cci		Crystal structure of phospho-cdk2 cyclin a in complex with a peptide containing both the substrate and recruitment sites of cdc6
2cdz		Crystal structure of the human p21-activated kinase 4 in complex with cgp74514a
2cgu		Identification of chemically diverse chk1 inhibitors by receptor-based virtual screening
2cgv		Identification of chemically diverse chk1 inhibitors by receptor-based virtual screening
2cgw		Identification of chemically diverse chk1 inhibitors by receptor-based virtual screening
2cgx		Identification of chemically diverse chk1 inhibitors by receptor-based virtual screening
2cjm		Mechanism of cdk inhibition by active site phosphorylation: cdk2 y15p t160p in complex with cyclin a structure
2cke		Human death-associated drp-1 kinase in complex with inhibitor
2clq		Structure of mitogen-activated protein kinase kinase kinase
2clx		4-arylazo-3,5-diamino-1h-pyrazole cdk inhibitors: sar study, crystal structure in complex with cdk2, selectivity, and cellular effects
2cn5		Crystal structure of human chk2 in complex with adp
2cn8		Crystal structure of human chk2 in complex with debromohymenialdisine
2cpk		Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase
2ds1		Human cyclin dependent kinase 2 complexed with the cdk4 inhibitor
2duv		Structure of cdk2 with a 3-hydroxychromones
2dwb		Aurora-a kinase complexed with amppnp
2dyl		Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (s287d, t291d)
2e14		The structure of erk2 in complex with fr148083
2e9n		Structure of h-chk1 complexed with a767085
2e9o		Structure of h-chk1 complexed with aa582939
2e9p		Structure of h-chk1 complexed with a771129
2e9u		Structure of h-chk1 complexed with a780125
2e9v		Structure of h-chk1 complexed with a859017
2erk		Phosphorylated map kinase erk2
2erz		Crystal structure of c-amp dependent kinase (pka) bound to hydroxyfasudil
2esm		Crystal structure of rock 1 bound to fasudil
2etk		Crystal structure of rock 1 bound to hydroxyfasudil
2etr		Crystal structure of rock i bound to y-27632
2eu9		Crystal structure of clk3
2euf		X-ray structure of human cdk6-vcyclin in complex with the inhibitor pd0332991
2ewa		Dual binding mode of pyridinylimidazole to map kinase p38
2exc		Inhibitor complex of jnk3
2exe		Crystal structure of the phosphorylated clk3
2exm		Human cdk2 in complex with isopentenyladenine
2f2c		X-ray structure of human cdk6-vcyclinwith the inhibitor aminopurvalanol
2f2u		Crystal structure of the rho-kinase kinase domain
2f49		Crystal structure of fus3 in complex with a ste5 peptide
2f57		Crystal structure of the human p21-activated kinase 5
2f7e		Pka complexed with (s)-2-(1h-indol-3-yl)-1-(5-isoquinolin-6- yl-pyridin-3-yloxymethyl-etylamine
2f7x		Protein kinase a bound to (s)-2-(1h-indol-3-yl)-1-[5-((e)-2- pyridin-4-yl-vinyl)-pyridin-3-yloxymethyl]-ethylamine
2f7z		Protein kinase a bound to (r)-1-(1h-indol-3-ylmethyl)-2-(2- pyridin-4-yl-[1,7]naphtyridin-5-yloxy)-ehylamine
2f9g		Crystal structure of fus3 phosphorylated on tyr182
2fa2		Crystal structure of fus3 without a peptide from ste5
2fh9		Structure and dimerization of the kinase domain from yeast snf1
2fsl		Mitogen activated protein kinase p38alpha (d176a+f327s) activating mutant form-a
2fsm		Mitogen activated protein kinase p38alpha (d176a+f327s) activating mutant form-b
2fso		Mitogen activated protein kinase p38alpha (d176a) activating mutant
2fst		Mitogen activated protein kinase p38alpha (d176a+f327l) activating mutant
2fum		Catalytic domain of protein kinase pknb from mycobacterium tuberculosis in complex with mitoxantrone
2fvd		Cyclin dependent kinase 2 (cdk2) with diaminopyrimidine inhibitor
2fys		Crystal structure of erk2 complex with kim peptide derived from mkp3
2g01		Pyrazoloquinolones as novel, selective jnk1 inhibitors
2g9x		Structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor nu6271
2gcd		Tao2 kinase domain-staurosporine structure
2gdo		4-(aminoalkylamino)-3-benzimidazole-quinolinones as potent chk1 inhibitors
2gfc		Camp-dependent protein kinase pka catalytic subunit with pki-5-24
2gfs		P38 kinase crystal structure in complex with ro3201195
2ghg		H-chk1 complexed with a431994
2ghl		Mutant mus musculus p38 kinase domain in complex with inhibitor pg-874743
2ghm		Mutated map kinase p38 (mus musculus) in complex with inhbitor pg-895449
2gmx		Selective aminopyridine-based c-jun n-terminal kinase inhibitors with cellular activity
2gnf		Protein kinase a fivefold mutant model of rho-kinase with y-
2gng		Protein kinase a fivefold mutant model of rho-kinase
2gnh		Pka five fold mutant model of rho-kinase with h1152p
2gni		Pka fivefold mutant model of rho-kinase with inhibitor fasudil (ha1077)
2gnj		Pka three fold mutant model of rho-kinase with y-27632
2gnl		Pka threefold mutant model of rho-kinase with inhibitor h- 1152p
2gph		Docking motif interactions in the map kinase erk2
2gtm		Mutated mouse p38 map kinase domain in complex with inhibitor pg-892579
2gtn		Mutated map kinase p38 (mus musculus) in complex with inhbitor pg-951717
2gu8		Discovery of 2-pyrimidyl-5-amidothiophenes as novel and potent inhibitors for akt: synthesis and sar studies
2h6d		Protein kinase domain of the human 5'-amp-activated protein kinase catalytic subunit alpha-2 (ampk alpha-2 chain)
2h96		Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-jun nh2-terminal kinase inhibitors
2h9v		Structural basis for induced-fit binding of rho-kinase to the inhibitor y27632
2hak		Catalytic and ubiqutin-associated domains of mark1/par-1
2hog		Crystal structure of chek1 in complex with inhibitor 20
2hw6		Crystal structure of mnk1 catalytic domain
2hw7		Crystal structure of mnk2-d228g in complex with staurosporine
2hxl		Crystal structure of chek1 in complex with inhibitor 1
2hxq		Crystal structure of chek1 in complex with inhibitor 2
2hy0		Crystal structure of chek1 in complex with inhibitor 22
2hy8		Pak1 complex with st2001
2i0e		Structure of catalytic domain of human protein kinase c beta ii complexed with a bisindolylmaleimide inhibitor
2i0h		The structure of p38alpha in complex with an arylpyridazinone
2i40		Cdk2/cyclin a complexed with a thiophene carboxamide inhibitor
2i6l		Crystal structure of human mitogen activated protein kinase (mapk6)
2iw6		Structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor
2iw8		Structure of human thr160-phospho cdk2-cyclin a f82h-l83v- h84d mutant with an o6-cyclohexylmethylguanine inhibitor
2iw9		Structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor
2iwi		Crystal structure of the human pim2 in complex with a ruthenium organometallic ligand ru1
2j0i		Crystal structure of the human p21-activated kinase 4
2j2i		Crystal structure of the humab pim1 in complex with ly333531
2j4z		Structure of aurora-2 in complex with pha-680626
2j50		Structure of aurora-2 in complex with pha-739358
2j51		Crystal structure of human ste20-like kinase bound to 5- amino-3-((4-(aminosulfonyl)phenyl)amino)-n-(2,6- difluorophenyl)-1h-1,2,4-triazole-1-carbothioamide
2j7t		Crystal structure of human serine threonine kinase-10 bound to su11274
2j90		Crystal structure of human zip kinase in complex with a tetracyclic pyridone inhibitor (pyridone 6)
2j9m		Crystal structure of cdk2 in complex with macrocyclic aminopyrimidine
2jam		Crystal structure of human calmodulin-dependent protein kinase i g
2jav		Human kinase with pyrrole-indolinone ligand
2jbo		Protein kinase mk2 in complex with an inhibitor (crystal form-1, soaking)
2jbp		Protein kinase mk2 in complex with an inhibitor (crystal form-2, co-crystallization)
2jc6		Crystal structure of human calmodulin-dependent protein kinase 1d
2jd5		Sky1p bound to npl3p-derived substrate peptide
2jdo		Structure of pkb-beta (akt2) complexed with isoquinoline-5- sulfonic acid (2-(2-(4-chlorobenzyloxy) ethylamino)ethyl) amide
2jdr		Structure of pkb-beta (akt2) complexed with the inhibitor a-
2jds		Structure of camp-dependent protein kinase complexed with a-
2jdt		Structure of pka-pkb chimera complexed with isoquinoline-5- sulfonic acid (2-(2-(4-chlorobenzyloxy) ethylamino)ethyl) amide
2jdv		Structure of pka-pkb chimera complexed with a-443654
2jed		The crystal structure of the kinase domain of the protein kinase c theta in complex with nvp-xaa228 at 2.32a resolution.
2jfl		Crystal structure of human ste20-like kinase (diphosphorylated form) bound to 5- amino-3-((4- (aminosulfonyl)phenyl)amino)-n-(2,6- difluorophenyl)-1h-1, 2, 4-triazole-1-carbothioamide
2jfm		Crystal structure of human ste20-like kinase (unliganded form)
2jgz		Crystal structure of phospho-cdk2 in complex with cyclin b
2jld
2no3		Novel 4-anilinopyrimidines as potent jnk1 inhibitors
2np8		Structural basis for the inhibition of aurora a kinase by a novel class of high affinity disubstituted pyrimidine inhibitors
2npq		A novel lipid binding site in the p38 alpha map kinase
2o0u		Crystal structure of human jnk3 complexed with n-{3-cyano-6- [3-(1-piperidinyl)propanoyl]-4,5,6,7-tetrahydrothieno[2,3- c]pyridin-2-yl}-1-naphthalenecarboxamide
2o2u		Crystal structure of human jnk3 complexed with n-(3-cyano-4, 5,6,7-tetrahydro-1-benzothien-2-yl)-2-fluorobenzamide
2o3p		Crystal structure of pim1 with quercetin
2o5k		Crystal structure of gsk3beta in complex with a benzoimidazol inhibitor
2o63		Crystal structure of pim1 with myricetin
2o64		Crystal structure of pim1 with quercetagetin
2o65		Crystal structure of pim1 with pentahydroxyflavone
2obj		Crystal structure of human pim-1 kinase in complex with inhibitor
2oh0		Crystal structure of protein kinase a in complex with pyridine-pyrazolopyridine based inhibitors
2oi4		Crystal structure of human pim1 in complex with fluorinated ruthenium pyridocarbazole
2ojf		Crystal structure of protein kinase a in complex with pyridine-pyrazolopyridine based inhibitors
2ojg		Crystal structure of erk2 in complex with n,n-dimethyl-4-(4- phenyl-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide
2oji		Crystal structure of erk2 in complex with n-benzyl-4-(4-(3- chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide
2ojj		Crystal structure of erk2 in complex with (s)-n-(1-(3- chloro-4-fluorophenyl)-2-hydroxyethyl)-4-(4-(3- chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide
2ok1		Crystal structure of jnk3 bound to n-benzyl-4-(4-(3- chlorophenyl)-1h-pyrazol-3-yl)-1h-pyrrole-2-carboxamide
2okr		Crystal structure of the p38a-mapkap kinase 2 heterodimer
2onl		Crystal structure of the p38a-mapkap kinase 2 heterodimer
2ou7		Structure of the catalytic domain of human polo-like kinase
2ow3		Glycogen synthase kinase-3 beta in complex with bis- (indole)maleimide pyridinophane inhibitor
2owb		Structure of the catalytic domain of human polo-like kinase
2oxd		Protein kinase ck2 in complex with tetrabromobenzoimidazole k17, k22 and k32 inhibitors
2oxx		Protein kinase ck2 in complex with tetrabromobenzoimidazole derivatives k17, k22 and k32
2oxy		Protein kinase ck2 in complex with tetrabromobenzoimidazole derivatives k17, k22 and k32
2oza		Structure of p38alpha complex
2p33		Synthesis and sar of aminopyrimidines as novel c-jun n- terminal kinase (jnk) inhibitors
2p3g		Crystal structure of a pyrrolopyridine inhibitor bound to mapkap kinase-2
2p55		X-ray structure of the human mitogen-activated protein kinase kinase 1 (mek1) in a complex with ligand and mgatp
2pe0		Crystal structure of human phosphoinositide-dependent protein kinase 1 (pdk1) 5-hydroxy-3-[1-(1h-pyrrol-2-yl)- eth-(z)-ylidene]-1,3-dihydro-indol-2-one complex
2pe1		Crystal structure of human phosphoinositide-dependent protein kinase 1 (pdk1) {2-oxo-3-[1-(1h-pyrrol-2-yl)-eth- (z)-ylidene]-2,3-dihydro-1h-indol-5-yl}-urea {bx-517} complex
2pe2		Crystal structure of human phosphoinositide-dependent protein kinase 1 (pdk1) 3-{5-[2-oxo-5-ureido-1,2-dihydro- indol-(3z)-ylidenemethyl]-1h-pyrrol-3-yl}-n-(2-piperidin-1- yl-ethyl)-benzamide complex
2phk		The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition
2pk9		Structure of the pho85-pho80 cdk-cyclin complex of the phosphate-responsive signal transduction pathway
2pkj		Crystal structure of f169a p38 kinase
2pmi		Structure of the pho85-pho80 cdk-cyclin complex of the phosphate-responsive signal transduction pathway with bound atp-gamma-s
2ptj		Crystal structure of f169r p38 kinase
2pto		Mutagenesis of p38 map kinase establishes key roles of phe169 in function and dynamics and reveals a novel dfg- out state
2puu		Crystal structure of p38 complex with 1-(5-tert-butyl-2-p- tolyl-2h-pyrazol-3-yl)-3-[4-(6-morpholin-4-ylmethyl- pyridin-3-yl)naphthalen-1-yl]urea
2pv5		Mutagenesis of p38 map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state
2pv8		Mutagenesis of p38 map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state
2pvh		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
2pvj		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
2pvk		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
2pvl		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
2pvm		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
2pvn		Structure-based design of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase ck2
2pvr		Crystal structure of the catalytic subunit of protein kinase ck2 (c-terminal deletion mutant 1-335) in complex with two sulfate ions
2pzy		Structure of mk2 complexed with compound 76
2q0n		Structure of human p21 activating kinase 4 (pak4) in complex with a consensus peptide
2qc6		Protein kinase ck2 in complex with dbc
2qcs		A complex structure between the catalytic and regulatory subunit of protein kinase a that represents the inhibited state
2qd9		P38 alpha map kinase inhibitor based on heterobicyclic scaffolds
2qg5		Cryptosporidium parvum calcium dependent protein kinase cgd7_1840
2qhm		Crystal structure of chek1 in complex with inhibitor 2a
2qhn		Crystal structure of chek1 in complex with inhibitor 1a
2qkr		Cryptosporidium parvum cyclin-dependent kinase cgd5_2510 with indirubin 3'-monoxime bound
2qnj		Kinase and ubiquitin-associated domains of mark3/par-1
2qr7		2.0a x-ray structure of c-terminal kinase domain of p90 ribosomal s6 kinase 2: se-met derivative
2qr8		2.0a x-ray structure of c-terminal kinase domain of p90 ribosomal s6 kinase 2 (rsk2)
2qur		Crystal structure of f327a/k285p mutant of camp-dependent protein kinase
2qvs		Crystal structure of type iia holoenzyme of camp-dependent protein kinase
2r0i
2r0u		Crystal structure of chek1 in complex with inhibitor 54
2r3f		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3g		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3h		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3i		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3j		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3k		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3l		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3m		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3n		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3o		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3p		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3q		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r3r		Crystal structure of cyclin-dependent kinase 2 with inhibitor
2r5t
2r64
2r7b
2r7i
2r9s		C-jun n-terminal kinase 3 with 3,5-disubstituted quinoline inhibitor
2rg5		Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11b
2rg6		Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11j
2rku		Structure of plk1 in complex with bi2536
2uue		Replace: a strategy for iterative design of cyclin binding groove inhibitors
2uv2		Crystal structure of human ste20-like kinase bound to 4-(4- (5-cyclopropyl-1h-pyrazol-3-ylamino)-quinazolin-2-ylamino)- phenyl)-acetonitrile
2uvx		Structure of pka-pkb chimera complexed with 7-azaindole
2uvy		Structure of pka-pkb chimera complexed with methyl-(4-(9h- purin-6-yl)-benzyl)-amine
2uvz		Structure of pka-pkb chimera complexed with c-phenyl-c-(4-( 9h-purin-6-yl)-phenyl)-methylamine
2uw0		Structure of pka-pkb chimera complexed with 6-(4-(4-(4- chloro-phenyl)-piperidin-4-yl)-phenyl)-9h-purine
2uw3		Structure of pka-pkb chimera complexed with 5-methyl-4- phenyl-1h-pyrazole
2uw4		Structure of pka-pkb chimera complexed with 2-(4-(5-methyl- 1h-pyrazol-4-yl)-phenyl)-ethylamine
2uw5		Structure of pka-pkb chimera complexed with (r)-2-(4- chloro-phenyl)-2-(4-1h-pyrazol-4-yl)-phenyl)-ethylamine
2uw6		Structure of pka-pkb chimera complexed with (s)-2-(4- chloro-phenyl)-2-(4-1h-pyrazol-4-yl)-phenyl)-ethylamine
2uw7		Structure of pka-pkb chimera complexed with 4-(4-chloro- phenyl)-4-(4-(1h-pyrazol-4-yl)-phenyl)-piperidine
2uw8		Structure of pka-pkb chimera complexed with 2-(4-chloro- phenyl)-2-phenyl-ethylamine
2uw9		Structure of pkb-beta (akt2) complexed with 4-(4-chloro- phenyl)-4-(4-(1h-pyrazol-4-yl)-phenyl)-piperidine
2uzb		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
2uzd		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
2uze		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
2uzl		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
2uzn		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
2uzo		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
2uzt		Pka structures of akt, indazole-pyridine inhibitors
2uzu		Pka structures of indazole-pyridine series of akt inhibitors
2uzv		Pka structures of indazole-pyridine series of akt inhibitors
2uzw		Pka structures of indazole-pyridine series of akt inhibitors
2v0d		Crystal structure of human cdk2 complexed with a thiazolidinone inhibitor
2v22		Replace: a strategy for iterative design of cyclin binding groove inhibitors
2v55
2v5q		Crystal structure of wild-type plk-1 kinase domain in complex with a selective darpin
2v7o		Crystal structure of human calcium-calmodulin-dependent protein kinase ii gamma
2vag		Crystal structure of di-phosphorylated human clk1 in complex with a novel substituted indole inhibitor
2vd5		Structure of human myotonic dystrophy protein kinase in complex with the bisindoylmaleide inhibitor bim viii
2vgo
2vgp		Crystal structure of aurora b kinase in complex with a aminothiazole inhibitor
2vn9		Crystal structure of human calcium calmodulin dependent protein kinase ii delta isoform 1, camkd
2vnw		Structure of pka-pkb chimera complexed with (1-(9h-purin-6- yl)piperidin-4-yl)methanamine
2vny		Structure of pka-pkb chimera complexed with (1-(9h-purin-6- yl)piperidin-4-yl)amine
2vo0		Structure of pka-pkb chimera complexed with c-(4-(4- chlorophenyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin- 4-yl)methylamine
2vo3		Structure of pka-pkb chimera complexed with c-(4-(4- chlorophenyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin- 4-yl)methylamine
2vo6		Structure of pka-pkb chimera complexed with 4-(4- chlorobenzyl)-1-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin- 4-ylamine
2vo7		Structure of pka complexed with 4-(4-chlorobenzyl)-1-(7h- pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-ylamine
2vrx		Structure of aurora b kinase in complex with zm447439
2vta		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vth		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vti		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vtj		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vtl		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vtm		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vtn		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vto		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vtp		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vtq		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vtr		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vts		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vtt		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vu3		Identification of n-(4-piperidinyl)-4-(2,6- dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment- based x-ray crystallography and structure based drug design.
2vv9		Cdk2 in complex with an imidazole piperazine
2vwi		Structure of the osr1 kinase, a hypertension drug target
2vx3
2vz6
2w05
2w06
2w0j
2w17
2w1c
2w1d
2w1e
2w1f
2w1g
2w1h
2w4o
2w5a
2w5b
2w5h
2w7x
2w96
2w99
2w9f
2w9z
2waj
2wei
2wel
2wev
2wfy
2wha
2whb
2wih
2wip
2wmq
2wmr
2wms
2wmt
2wmu
2wmv
2wmw
2wmx
2wnt
2wo6
2wqe
2wu6
2wu7
2ywp		Crystal structure of chk1 with a urea inhibitor
2yza		Crystal structure of kinase domain of human 5'-amp- activated protein kinase alpha-2 subunit mutant (t172d)
2z7l		Unphosphorylated mitogen activated protein kinase erk2 in complex with (4-{[5-carbamoyl-4-(3-methylanilino)pyrimidin 2-yl]amino}phenyl)acetic acid
2z7q		Crystal structure of the n-terminal kinase domain of human rsk-1 bound to amp-pcp
2z7r		Crystal structure of the n-terminal kinase domain of human rsk1 bound to staurosporine
2z7s		Crystal structure of the n-terminal kinase domain of human rsk1 bound to purvalnol a
2zaz		Crystal structure of p38 in complex with 4-anilino quinoline inhibitor
2zb0		Crystal structure of p38 in complex with biphenyl amide inhibitor
2zb1		Crystal structure of p38 in complex with biphenyl amide inhibitor
2zdt
2zdu
2zjw
2zmc		Crystal structure of human mitotic checkpoint kinase mps1 catalytic domain apo form
2zmd		Crystal structure of human mps1 catalytic domain t686a mutant in complex with sp600125 inhibitor
2zoq
2zv2
3a60
3a61
3a62
3be9
3bgp		Human pim-1 complexed with a benzoisoxazole inhibitor vx1
3bgq		Human pim-1 kinase in complex with an triazolo pyridazine inhibitor vx2
3bgz		Human pim-1 kinase in complex with diphenyl indole inhibitor vx3
3bhh		Crystal structure of human calcium/calmodulin-dependent protein kinase iib isoform 1 (camk2b)
3bht		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 3
3bhu		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 5
3bhv		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor variolin b
3bhy		Crystal structure of human death associated protein kinase (dapk3) in complex with a beta-carboline ligand
3blh		Crystal structure of human cdk9/cyclint1
3blq		Crystal structure of human cdk9/cyclint1 in complex with atp
3blr		Crystal structure of human cdk9/cyclint1 in complex with flavopiridol
3bqc		High ph-value crystal structure of emodin in complex with the catalytic subunit of protein kinase ck2
3bqr		Crystal structure of human death associated protein kinase (dapk3) in complex with an imidazo-pyridazine ligand
3bv2		Morpholino pyrrolotriazine p38 alpha map kinase inhibitor compound 30
3bv3		Morpholino pyrrolotriazine p38 alpha map kinase inhibitor compound 2
3bwf		Crystal structure of the human pim1 in complex with an osmium compound
3bwj
3bx5		P38 alpha map kinase complexed with bms-640994
3c0g		Cask cam-kinase domain- 3'-amp complex, p1 form
3c0h		Cask cam-kinase domain- amppnp complex, p1 form
3c0i		Cask cam-kinase domain- 3'-amp complex, p212121 form
3c13		Low ph-value crystal structure of emodin in complex with the catalytic subunit of protein kinase ck2
3c4e		Pim-1 kinase domain in complex with 3-aminophenyl-7- azaindole
3c4w		Crystal structure of g protein coupled receptor kinase 1 bound to atp and magnesium chloride at 2.7a
3c4x		Crystal structure of g protein coupled receptor kinase 1 bound to atp and magnesium chloride at 2.9a
3c4y		Crystal structure of apo form of g protein coupled receptor kinase 1 at 7.51a
3c4z		Crystal structure of g protein coupled receptor kinase 1 bound to adp and magnesium chloride at 1.84a
3c50		Crystal structure of g protein coupled receptor kinase 1 bound to adp and magnesium chloride at 2.6a
3c51		Crystal structure of g protein coupled receptor kinase 1 bound to adp and magnesium chloride at 3.55a
3c5u		P38 alpha map kinase complexed with a benzothiazole based inhibitor
3c9w		Crystal structure of erk-2 with hypothemycin covalently bound
3cek		Crystal structure of human dual specificity protein kinase (ttk)
3cg2		P38 alpha kinase complexed with a pyrazolo-pyrimidine based inhibitor
3cgf		Irak-4 inhibitors (part ii)- a structure based assessment of imidazo[1,2 a]pyridine binding
3cgo		Irak-4 inhibitors (part ii)- a structure based assessment of imidazo[1,2 a]pyridine binding
3cik
3ckw		Crystal structure of sterile 20-like kinase 3 (mst3, stk24)
3ckx		Crystal structure of sterile 20-like kinase 3 (mst3, stk24) in complex with staurosporine
3coh
3coi		Crystal structure of p38delta kinase
3cok		Crystal structure of plk4 kinase
3com		Crystal structure of mst1 kinase
3cqu		Crystal structure of akt-1 complexed with substrate peptide and inhibitor
3cqw		Crystal structure of akt-1 complexed with substrate peptide and inhibitor
3ctq		Structure of map kinase p38 in complex with a 1-o-tolyl-1,2, 3-triazole-4-carboxamide
3cxw		Crystal structure of human proto-oncogene serine threonine kinase (pim1) in complex with a consensus peptide and a beta carboline ligand i
3cy2		Crystal structure of human proto-oncogene serine threonine kinase (pim1) in complex with a consensus peptide and a beta carboline ligand ii
3cy3		Crystal structure of human proto-oncogene serine threonine kinase (pim1) in complex with a consensus peptide and the jnk inhibitor v
3d0e
3d14
3d15
3d2i
3d2k
3d5u
3d5v
3d5w
3d5x
3d7z		Crystal structure of p38 kinase in complex with a biphenyl amide inhibitor
3d83		Crystal structure of p38 kinase in complex with a biphenyl amide inhibitor
3d9v		Crystal structure of rock i bound to h-1152p a di- methylated variant of fasudil
3da6
3dae
3daj		Crystal structure of aurora a complexed with an inhibitor discovered through site-directed dynamic tethering
3dak
3db6		Crystal structure of an activated (thr->asp) polo-like kinase 1 (plk1) catalytic domain in complex with compound
3db8
3dbc
3dbd
3dbe
3dbf
3dbq
3dcv		Crystal structure of human pim1 kinase complexed with 4-(4- hydroxy-3-methyl-phenyl)-6-phenylpyrimidin-2(1h)-one
3ddp		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor cr8
3ddq		Structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor roscovitine
3dfa		Crystal structure of kinase domain of calcium-dependent protein kinase cgd3_920 from cryptosporidium parvum
3dfc
3dgk
3dj5
3dj6
3dj7
3dls
3dnd
3dne
3dog
3ds6
3dt1
3du8
3dv3
3dxn
3dy7
3e3b
3e3p		Glycogen synthase kinase from leishmania major
3e5a
3e7o
3e87
3e88
3e8c
3e8d
3e8e
3e8n
3e92
3e93
3eb0
3efw
3eh9
3eha
3eid
3ej1
3elj
3enm
3eoc
3eqb
3eqc
3eqd
3eqf
3eqg
3eqh
3eqi
3erk		The complex structure of the map kinase erk2/sb220025
3ezr
3ezv
3f2a
3f3z
3f5g
3f5u
3f5x
3f61
3f69
3f7z
3f88
3f9n
3fc1
3fc2
3fdn
3fe3
3fhi
3fi2
3fi3
3fjq
3fl5
3fme
3fpm
3fv8
3fwq
3fxz
3fy0
3fyj
3fyk
3fz1
3g33
3g90
3g9l
3g9n
3gbz
3gc0
3gc7
3gc8
3gc9
3gcp
3gcq
3gcs
3gcu
3gcv
3gfe
3gfw
3ggf
3gi3
3gp0
3h0y
3h0z
3h10
3h30
3h4j
3h9f
3h9o
3ha6
3ha8
3hdm
3hdn
3hec
3heg
3hko
3hl7
3hll
3hp2
3hp5
3hrb
3hrc
3hrf
3hv3
3hv4
3hv5
3hv6
3hv7
3hvc
3hx4
3hyh
3hzt
3i6u
3i6w
3i79
3idb
3idc
3ig7
3igg
3igo
3iph
3is5
3iw4
3iw5
3iw6
3iw7
3iw8
3jpv
3juh
3jvr
3jvs
3jxw
3jy0
3jya
3k2l
3k3i
3k3j
4erk		The complex structure of the map kinase erk2/olomoucine

Links (links to other resources describing this domain)
PFAM pkinase
INTERPRO IPR002290

PFAM	pkinase
INTERPRO	IPR002290